ホーム › 肝臓がん（肝細胞がん） › イリノイ州 › Chicago
Chicago、ILにおける肝臓がん（肝細胞がん）の臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、肝臓がん（肝細胞がん）に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #26, Chicago
National Liver Cancer Screening Trial
被験者募集中第4相
- Northwestern University, Chicago
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
被験者募集中第1/2相
- Local Institution - 0107, Chicago
Defining the Ablative Dose for Y-90 TARE
被験者募集中第2相
- Northwestern University, Chicago
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
被験者募集中観察研究
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
被験者募集中第3相
- Research Site, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Lurie Children's Hospital-Chicago, Chicago
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
被験者募集中第3相
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
被験者募集中第2相
- University of Chicago Comprehensive Cancer Center, Chicago
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
被験者募集中観察研究
- Rush University Medical Center, Chicago
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
被験者募集中第1/2相
- Northwestern University, Chicago
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
被験者募集中第1相
- Clinical Trial Site, Chicago
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
被験者募集中第2相
- Northwestern University, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
被験者募集中第4相
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chicago
The Dragon PLC Trial (DRAGON-PLC)
被験者募集中
- Rush University Medical Center, Chicago
他の都市における肝臓がん（肝細胞がん）の試験
- Houston, TX31件の研究
- New York City, NY24件の研究
- Dallas, TX19件の研究
- Los Angeles, CA19件の研究
- Boston, MA18件の研究
- Cleveland, OH18件の研究
- Philadelphia, PA16件の研究
- Pittsburgh, PA15件の研究
- San Francisco, CA14件の研究
- Orange, CA14件の研究
- Jacksonville, FL14件の研究
- San Antonio, TX13件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん59件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肺がん41件の研究
- 肥満症41件の研究
- 卵巣がん36件の研究
- 大腸癌34件の研究
- 脳卒中34件の研究
- 心不全31件の研究
- 過体重29件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。